Polaris AI Pharma's Operating Profit Surges 1,712% Last Year... 'Profitability Quantum Leap' After Joining Polaris Group View original image

Polaris AI Pharma, a company specializing in active pharmaceutical ingredients (APIs) and contract development and manufacturing (CDMO), has achieved remarkable improvement in its performance, driven by company-wide structural reforms and the increased value of strategic investment assets following its incorporation into the Polaris Group.


On March 9, Polaris AI Pharma announced that, on a standalone basis for the previous year, it recorded sales of 55.5 billion won, operating profit of 3.2 billion won, and net profit of 6.2 billion won.


In particular, operating profit surged by 1,712% compared to the previous year (approximately 200 million won), and net profit also jumped by about 56% compared to the previous year (3.9 billion won), demonstrating a significant improvement in profitability.


Although sales declined slightly by about 6.8% year-on-year, the company explained that this resulted from a management strategy focused on 'strengthening the profitability structure' rather than mere external growth.


The company noted that this performance is not a one-off rebound, but rather signifies its full-fledged entry into a trajectory of profit generation through qualitative growth.


The main driver behind this dramatic increase in profit margin was a successful cost structure overhaul. Temporary expenses, such as severance pay arising during the acquisition process by Polaris Group in 2024, were resolved, resulting in a base effect. In addition, company-wide resource optimization at the group level led to a significant reduction in selling and administrative expenses, thereby maximizing operational leverage.


The substantial increase in net profit was also strongly aided by the visible achievements of strategic investment companies. Firstly, QuadMedicine, a company specializing in microneedle technology, succeeded in being listed on the stock market, thus realizing the value of Polaris AI Pharma’s equity stake.


Furthermore, Israel-based cancer treatment solutions company Alpha Tau Medical recently obtained regulatory approval in Japan to sell its head and neck cancer radiation therapy device, Alpha DaRT®, which provided a significant boost to the company's valuation.


A representative from Polaris AI Pharma stated, "If 2024 was the year for laying the groundwork to create synergy with Polaris Group, then 2025 will mark the beginning of a 'profitability quantum leap,' having completely eliminated temporary cost burdens and entering full-scale profit generation. Based on a stable financial structure, we will continue to expand our high value-added businesses and do our utmost to enhance shareholder value."



Meanwhile, Polaris AI Pharma is accelerating efforts not only to restore current profitability but also to secure future growth engines. Together with its affiliate Polaris Office, it is developing a pharmaceutical AI solution called 'Pharma ASK-Doc' using retrieval-augmented generation (RAG) technology. Through this, the company aims to build AI models specialized for the pharmaceutical domain and actively expand its portfolio into high value-added, AI-driven pharmaceutical businesses, including new drug development support and clinical data analysis.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing